602 related articles for article (PubMed ID: 33110473)
21. Cardiac complications in cancer treatment - A review.
Li X; Liu M; Sun R; Zeng Y; Chen S; Zhang P
Hellenic J Cardiol; 2017; 58(3):190-193. PubMed ID: 28011332
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress.
Angsutararux P; Luanpitpong S; Issaragrisil S
Oxid Med Cell Longev; 2015; 2015():795602. PubMed ID: 26491536
[TBL] [Abstract][Full Text] [Related]
23. Cardiotoxicity of systemic agents used in breast cancer.
Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
[TBL] [Abstract][Full Text] [Related]
24. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
25. Cardiotoxicity and cardioprotection in childhood cancer.
Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
[TBL] [Abstract][Full Text] [Related]
26. Cardiotoxicity linked to anticancer agents and cardioprotective strategy.
Khairnar SI; Kulkarni YA; Singh K
Arch Pharm Res; 2022 Oct; 45(10):704-730. PubMed ID: 36306018
[TBL] [Abstract][Full Text] [Related]
27. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
28. [Cardiotoxicity of Cancer Chemotherapy - Mechanisms and Therapeutic Approach].
Akazawa H
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2058-2063. PubMed ID: 29361617
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics.
Abdul-Rahman T; Dunham A; Huang H; Bukhari SMA; Mehta A; Awuah WA; Ede-Imafidon D; Cantu-Herrera E; Talukder S; Joshi A; Sundlof DW; Gupta R;
Curr Probl Cardiol; 2023 Apr; 48(4):101591. PubMed ID: 36621516
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Toxicities in Pediatric Cancer Survivors.
Ryan TD; Nagarajan R; Godown J
Cardiol Clin; 2019 Nov; 37(4):533-544. PubMed ID: 31587793
[TBL] [Abstract][Full Text] [Related]
31. Left Ventricular Dysfunction in Cancer Treatment: Is it Relevant?
Kenigsberg B; Wellstein A; Barac A
JACC Heart Fail; 2018 Feb; 6(2):87-95. PubMed ID: 29413379
[TBL] [Abstract][Full Text] [Related]
32. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.
Berardi R; Caramanti M; Savini A; Chiorrini S; Pierantoni C; Onofri A; Ballatore Z; De Lisa M; Mazzanti P; Cascinu S
Crit Rev Oncol Hematol; 2013 Oct; 88(1):75-86. PubMed ID: 23522920
[TBL] [Abstract][Full Text] [Related]
33. Cancer chemotherapy induces cardiotoxicity by targeting cardiac stem cells.
Li YM; Guo YP; Liu Y
J Cell Mol Med; 2010 Nov; 14(11):2630-2. PubMed ID: 20874720
[TBL] [Abstract][Full Text] [Related]
34. [Cardiotoxicity of cancer therapy].
Marek J; Linhart A; Rucklová Z; Haber J; Korínek J
Vnitr Lek; 2011 May; 57(5):472-84. PubMed ID: 21695928
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.
Mihalcea DJ; Florescu M; Vinereanu D
Am J Ther; 2017; 24(1):e3-e11. PubMed ID: 27145188
[TBL] [Abstract][Full Text] [Related]
36. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
[TBL] [Abstract][Full Text] [Related]
37. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
38. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
Nelson-Veniard M; Thambo JB
Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
[TBL] [Abstract][Full Text] [Related]
39. Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
Mozolevska V; Schwartz A; Cheung D; Goyal V; Shaikh B; Dingman B; Kim E; Mittal I; Asselin CY; Edel A; Ravandi A; Thliveris J; Singal PK; Czaykowski P; Jassal DS
Am J Physiol Heart Circ Physiol; 2019 Mar; 316(3):H446-H458. PubMed ID: 30499710
[TBL] [Abstract][Full Text] [Related]
40. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
